A Study of MK-7240 in Healthy Participants (MK-7240-009)

NCT07405177 | Recruiting Phase 1 FDA Drug

• 2 other identifiers: 7240-009MK-7240-009
• Study Type: interventional
• Target: 330
• Locations: 1 country
• Sites: 2

Brief Summary

The goal of this study is to learn what happens to MK-7240 in a healthy person's body over time (pharmacokinetic or PK study). Researchers also want to learn about the safety of MK-7240 and if people tolerate it.

Conditions

Healthy

Outcome Measures

Primary Outcomes (3)

• Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of Tulisokibart

  Blood samples will be collected to determine the AUC0-inf of tulisokibart.

  At designated timepoints up to 14 weeks

• Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-Last) of Tulisokibart

  Blood samples will be collected to determine the AUC0-last of tulisokibart.

  At designated timepoints up to 14 weeks

• Maximum Plasma Concentration (Cmax) of Tulisokibart

  Blood samples will be collected to determine the Cmax of tulisokibart.

  At designated timepoints up to 14 weeks

Secondary Outcomes (9)

• Number of Participants Who Experience an Adverse Event (AE)

  At designated timepoints up to 14 weeks

• Number of Participants Who Discontinue Study Due to an AE

  At designated timepoints up to 14 weeks

• Time to Maximum Plasma Concentration (Tmax) of Tulisokibart

  At designated timepoints up to 14 weeks

• Apparent Clearance (CL/F) of Tulisokibart

  At designated timepoints up to 14 weeks

• Apparent Volume of Distribution (V/F) of Tulisokibart

  At designated timepoints up to 14 weeks

Study Arms (2)

Arm 1: Tulisokibart Form 1

EXPERIMENTAL

Participants will receive tulisokibart form 1.

Biological: Tulisokibart Form 1

Arm 2: Tulisokibart Form 2

EXPERIMENTAL

Participants will receive tulisokibart form 2.

Biological: Tulisokibart Form 2

Interventions

Tulisokibart Form 1 BIOLOGICAL

Solution for injection.

Also known as: MK-7240

Arm 1: Tulisokibart Form 1

Tulisokibart Form 2 BIOLOGICAL

Solution for injection.

Also known as: MK-7240

Arm 2: Tulisokibart Form 2

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Has a body-mass index (BMI) between 18 and 32 kg/m\^2

You may not qualify if:

• Has a history of more than 1 episode of herpes zoster infection or history of disseminated herpes zoster infection
• Has a history of or current active tuberculosis (TB) infection or history of latent TB that was not fully treated

Sponsors & Collaborators

• Merck Sharp & Dohme LLC: lead

Study Sites (2)

Nucleus Network ( Site 0002)

Brisbane, Queensland, 4006, Australia

RECRUITING

Nucleus Network ( Site 0001)

Melbourne, Victoria, 3004, Australia

RECRUITING

Related Links

• Merck Clinical Trials Information

Study Officials

• Medical Director

  Merck Sharp & Dohme LLC

  STUDY DIRECTOR

Central Study Contacts

Toll Free Number

CONTACT

1-888-577-8839; Trialsites@msd.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 5, 2026
• First Posted: February 12, 2026
• Study Start: March 5, 2026
• Primary Completion (Estimated): September 3, 2026
• Study Completion (Estimated): September 3, 2026
• Last Updated: April 8, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will share

Locations

AU (2)